Introduction: A critical requirement in the management of gut NETs is a blood biomarker test that is sensitive, specific and reproducible.
Aim(s): Evaluate a PCR-based 51 transcript signature to detect tumors, compared to Chromogranin A (CgA) and examine PPI use since they commonly cause false positive CgA tests.
Materials and methods: Group 1: 125 prospectively collected NETs: gastroenteropancreatic NETs (n=91, including 42 pancreatic and 40 small intestinal NETs), carcinoids of unknown primary (n=18) and other sites (n=16). Group 2 included prospectively collected non-NET patients receiving PPIs (>1 months) (dyspepsia: n=19, GERD: n=6, pancreatitis: n=4) and 50 controls. All samples were analyzed by PCR (NET marker genes) and ELISA (DAKO-CgA).
Conference: 11th Annual ENETS Conference 2014 (2014)
Presenting Author: Professor Irvin M Modlin
To read results and conclusion, please login ...
Further abstracts you may be interested in